Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for RTW Biotech Opportunities's EV-to-OCF or its related term are showing as below:
LSE:RTW'
s EV-to-OCF Range Over the Past 10 Years
Min: -10.22 Med: -2.98 Max: 30.75
Current: 7.84
During the past 8 years, the highest EV-to-OCF of RTW Biotech Opportunities was 30.75. The lowest was -10.22. And the median was -2.98.
LSE:RTW's EV-to-OCF is ranked worse than 54.62% of 1505
companies
in the Asset Management industry
Industry Median: 5.86
vs LSE:RTW: 7.84
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RTW Biotech Opportunities's PE Ratio (TTM) for today is calculated as:
RTW Biotech Opportunities's share price for today is $2.58.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RTW Biotech Opportunities's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RTW Biotech Opportunities EV-to-OCF Related Terms
RTW Biotech Opportunities EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, RTW Biotech Opportunities's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RTW Biotech Opportunities EV-to-OCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, RTW Biotech Opportunities's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where RTW Biotech Opportunities's EV-to-OCF falls into.
RTW Biotech Opportunities's current Enterprise Value is $825.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. RTW Biotech Opportunities's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $105.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RTW Biotech Opportunities (LSE:RTW) has a EV-to-OCF of 7.84 as of Aug. 21, 2026. According to the industry distribution chart, RTW Biotech Opportunities ranks #822 out of 1505 companies in the Asset Management industry, placing it in the top 54.6%.
Is RTW Biotech Opportunities' EV-to-OCF too high?
RTW Biotech Opportunities' current EV-to-OCF is 7.84. The Asset Management industry median EV-to-OCF is 5.86. RTW Biotech Opportunities' value of 7.84 is 33.8% above this industry median. Based on the distribution chart, RTW Biotech Opportunities ranks #822 out of 1505 companies in the Asset Management industry, which is below the industry midpoint. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' EV-to-OCF compare to BLK and BX?
According to the Asset Management industry distribution chart, RTW Biotech Opportunities ranks #822 out of 1505 companies for EV-to-OCF. This places RTW Biotech Opportunities in the lower half of its industry. The industry median EV-to-OCF is 5.86. RTW Biotech Opportunities' value of 7.84 is 33.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for an Asset Management company?
The median EV-to-OCF among Asset Management companies is 5.86, based on 1,505 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RTW Biotech Opportunities's current EV-to-OCF of 7.84 is 33.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median EV-to-OCF is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RTW Biotech Opportunities's current EV-to-OCF is 7.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current EV-to-OCF of 7.84. The current EV-to-OCF is 7.84 and 33.8% above the Asset Management industry median of 5.86. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current EV-to-OCF is 7.84 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score
Get the complete analysis for LSE:RTW
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RTW has been successfully added to your 
